SMi Group Ltd.

Hear from leading industry experts from major pharmaceutical companies about compliance challenges in KOL interaction..

This year’s event will focus on the utility of nanotechnology to aid the delivery and development of novel therapeutics in the field of RNAi, miRNA and siRNA.

With over 100 industry professionals attending, this event provides an ideal learning, networking and betterment opportunity. This is a must attend event if you want to stay ahead of the competitive curve and expand your understanding of the field

Hear in-depth analyses of the very latest In-Vitro, In-Silico developments and DMPK profile optimisation. Get to grips with compounds for Brain and CNS penetration, computational approaches and predictive models including protein modelling.

Engaging with patients: what's the best language to communicate with your pharma community

Trends and future market environment, how will this hinder or enhance growth and profitability?

Why strategies need to be in place right now to address provisions that do not take effect until March 2013 and how cycles of patent filings over periods of 12, 18 and 30 months can be structered under the new first -to-file regime

Characterisaion of ADC's is a crtitical step for both research and development of efficacious and safe therapeutics

SMi are proud to present their 7th annual ADMET conference on 9th & 10th July 2012 in London,

SMi are proud to present their 4th annual KOL Management & MSL Best Practice in Europe conference taking place on 2nd & 3rd July 2012, in Basel, Switzerland .